This site is intended for patients in the UK who have been prescribed PIQRAY®▼ (alpelisib) + fulvestrant.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Login

To continue, enter the password in the space below.

If you do not know the website password, please consult your PIQRAY®▼ (alpelisib) + fulvestrant patient brochure or ask your doctor.

PIQRAY® is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.1

 

Reference

  1. PIQRAY® (alpelisib) Summary of Product Characteristics.

 

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

 

PIQ20-C018c September 2020.